Data gathered: April 15
AI Stock Analysis - Merck & Company (MRK)
Analysis generated February 14, 2025. Powered by Chat GPT.
Merck & Co., Inc. (MRK) is a global healthcare company headquartered in Kenilworth, New Jersey. The company focuses on several areas of medicine, including oncology, vaccines, infectious diseases, and animal health. Founded in 1891, Merck's mission revolves around discovering, developing, manufacturing, and marketing innovative pharmaceuticals to solve growing medical challenges.
Stock Alerts - Merck & Company (MRK)
 |
Merck & Company | April 14 Job postings are down by 25.3% in the last couple of days. |
|
Merck & Company | April 10 Price is down by -5.5% in the last 24h. |
|
Merck & Company | April 8 Job postings are down by 43.6% in the last couple of days. |
|
Merck & Company | April 8 Gil Cisneros (member of U.S. congress) is selling shares |
Alternative Data for Merck & Company
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $79.17 |
| Target Price | Sign up |
| Volume | 15,790,000 |
| Market Cap | $199B |
| Year Range | $77.55 - $116.69 |
| Dividend Yield | 4.09% |
| PE Ratio | 11.75 |
| Analyst Rating | 59% buy |
| Earnings Date | April 24 '25 |
| Industry | Drug Manufacturers |
In the news
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRKApril 14 - Finnhub |
|
 |
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?April 14 - Yahoo |
|
Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds?April 14 - Yahoo |
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 13 - Finnhub |
|
MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 13 - Finnhub |
|
|
Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires?April 13 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 15.6B | 924M | 14.7B | 3.74B | 6.93B | 1.720 |
| Q3 '24 | 16.7B | 4.08B | 12.6B | 3.16B | 5.61B | 1.570 |
| Q2 '24 | 16.1B | 3.75B | 12.4B | 5.46B | 7.45B | 2.280 |
| Q1 '24 | 15.8B | 3.54B | 12.2B | 4.76B | 6.74B | 2.070 |
| Q4 '23 | 14.6B | 3.34B | 11.3B | -1.23B | 679M | 0.030 |
Insider Transactions View All
| Oosthuizen Johannes Jacobus filed to sell 30,705 shares at $84.1. February 20 '25 |
| Williams David Michael filed to sell 24,123 shares at $85.3. February 13 '25 |
| Downing Cristal N filed to sell 7,085 shares at $88.8. February 7 '25 |
| THULIN INGE G filed to buy 2,933 shares at $88.3. February 7 '25 |
| BAKER DOUGLAS M JR filed to buy 16,000 shares at $88.5. February 7 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.36 0% | 50 |
 |
Eli Lilly and CompanyLLY |
$754.35 0% | 69 |
 |
PfizerPFE |
$22.12 0% | 32 |
 |
AstrazenecaAZN |
$68.01 0% | 42 |
 |
AbbVieABBV |
$179.1 0% | 35 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gil Cisneros |
Apr 8, 25 | Sell | $15K - $50K |
| Rob Bresnahan |
Mar 28, 25 | Sell | $15K - $50K |
| Jefferson Shreve |
Mar 10, 25 | Buy | $15K - $50K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Merck & Company?
The Market Cap of Merck & Company is $199B.
What is Merck & Company's PE Ratio?
As of today, Merck & Company's PE (Price to Earnings) ratio is 11.75.
When does Merck & Company report earnings?
Merck & Company will report its next earnings on April 24 '25.
What is the current stock price of Merck & Company?
Currently, the price of one share of Merck & Company stock is $79.17.
How can I analyze the MRK stock price chart for investment decisions?
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Does MRK offer dividends to its shareholders?
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 4.09%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Merck & Company?
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.